ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Monoclonal antibodies"

  • 2021 American Transplant Congress

    Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients

    Z. A. Yetmar1, E. Beam1, J. C. O'Horo1, R. Ganesh2, D. M. Bierle2, L. Brumble3, M. T. Seville4, R. R. Razonable1

    1Infectious Diseases, Mayo Clinic, Rochester, MN, 2General Internal Medicine, Mayo Clinic, Rochester, MN, 3Infectious Diseases, Mayo Clinic, Jacksonville, FL, 4Infectious Diseases, Mayo Clinic, Scottsdale, AZ

    *Purpose: Bamlanivimab and casirivimab-imdevimab are authorized for emergency use treatment of mild-to-moderate COVID-19 in patients at high-risk for progression to severe disease or hospitalization. For…
  • 2021 American Transplant Congress

    A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of At-1501

    S. Perrin1, A. Gill2, C. Gill2, P. Gustafson1

    1Novus Therapeutics, Irvine, CA, 2ALS Therapy Development Institute, Cambridge, MA

    *Purpose: Execute a phase 1 study of AT-1501 to assess safety, pharmacokinetics, and functional activity.*Methods: The study employed a placebo-controlled, sequential, dose-escalation design. 28 healthy…
  • 2021 American Transplant Congress

    Pharmacokinetic and Toxicity Studies of an Anti CD40L Antibody, At-1501 in Rhesus Macaques

    S. Perrin1, A. Gill2, C. Gill2, F. Vieira2, K. Thompson2

    1Novus Therapeutics, Irvine, CA, 2ALS Therapy Development Institute, Cambridge, MA

    *Purpose: CD40L is a costimulatory receptor for CD40 found on T helper cells. Binding of CD40L on T cells to CD40 on antigen presenting cells…
  • 2021 American Transplant Congress

    The Development and Characterization of AT1501, an Anti CD40L Antibody Lacking Fc Effector Function

    S. Perrin1, A. Gill2, C. Gill2, F. Vieira2, K. Thompson2, J. Lincecum2, B. Jiang2

    1Novus Therapeutics, Irvine, CA, 2ALS Therapy Development Institute, Cambridge, MA

    *Purpose: CD40L is a costimulatory type II membrane receptor for CD40. The binding of CD40L on T helper cells to CD40 on antigen presenting cells…
  • 2021 American Transplant Congress

    Nurse and Nurse Practitioner-lead Monoclonal Antibody Initiative for Solid Organ Transplant (sot) Recipients with Covid-19

    W. Cochran1, R. Avery2, D. Brennan2, N. Lawrence2, A. Brown2, S. Sullivan2, B. Adams2, M. McCarthy2, S. Ellis2, F. Naqvi2, E. Kraus2, N. Alachkar2, S. Alasfar2, F. Al Ammary2, J. Horn2, L. Hartman2, L. Fessler2, S. Purekal2, Z. Siddiqui2, D. Carter2, J. Ficke2, M. Kantsiper2, L. Boyer2, I. Gupta2, A. Gurakar2, D. Ostrander2, J. Langlee2, S. Shoham2, K. Marr2, P. Shah2

    1Johns Hopkins Comprehensive Transplant Center, Baltimore, MD, 2Johns Hopkins, Baltimore, MD

    *Purpose: Monoclonal antibody (mAB) infusion (bamlanivimab or casirivimab/imdevimab) for symptomatic, non-hypoxemic, high-risk outpatients with COVID-19 infection, is an available early intervention for COVID-19+ SOT recipients.…
  • 2021 American Transplant Congress

    Bamlanivimab for Covid-19 in Kidney Transplant Patients

    M. Y. Jan, S. El-Sayegh, M. S. Yaqub, D. P. Mishler, O. Adebiyi, M. D. Anderson, T. E. Taber, A. Sharfuddin

    Nephrology, Indiana University School of Medicine, Indianapolis, IN

    *Purpose: Treatment options for patients with COVID 19 have limited efficacy in reducing severity and duration of viral symptoms as well as progression to severe…
  • 2020 American Transplant Congress

    Pneumocystis Pneumonia Occurrence and Prophylaxis Duration in Kidney Transplant Recipients According to Perioperative Treatment with Rituximab

    Y. Ko, Y. Kim, D. Han, H. Kwon

    Department of Surgery, Division of Kidney and Pancreas Transplant, AMC, Seoul, Korea, Republic of

    *Purpose: Pneumocystis pneumonia (PCP) is a life-threatening fungal infection that can occur in kidney transplantation (KT) recipients. A growing number of KT recipients are receiving…
  • 2020 American Transplant Congress

    Three-Month Results of a Phase 2 Trial Evaluating Clazakizumab in Late Antibody-Mediated Rejection – Early Impact of Interleukin-6 Blockade on Donor-Specific Antibody Levels, Rejection Morphology and Gene Expression

    G. A. Böhmig1, M. Dürr2, B. Jilma3, F. Eskandary1, E. Chong4, S. Schranz3, K. Doberer1, M. Wahrmann1, A. Borski1, H. Regele5, J. Kläger5, R. Reindl-Schwaighofer1, J. Reeve6, K. Budde2, P. F. Halloran6

    1Department of Medicine III, Medical University of Vienna, Vienna, Austria, 2Nephrology Department, Charité Berlin, Berlin, Germany, 3Dept. of Clin. Pharmacology, Medical University of Vienna, Vienna, Austria, 4Vitaeris Inc., Vancouver, BC, Canada, 5Dept. of Clin. Pathology, Medical University of Vienna, Vienna, Austria, 6Alberta Transplant Applied Genomics Centre, ATAGC, University of Alberta, Edmonton, AB, Canada

    *Purpose: Targeting Interleukin-6 (IL-6) is a promising strategy to counteract antibody-mediated rejection (ABMR). This phase 2 trial (NCT03444103) was designed to evaluate the safety and…
  • 2020 American Transplant Congress

    New Strategy to Maximize Nanomedicine Delivery During Ex Vivo Organ Perfusion

    C. Albert1, L. Bracaglia1, A. Koide2, C. M. Edwards3, T. Lysyy3, J. S. Pober4, M. Saltzman1, S. Koide2, G. Tietjen3

    1Biomedical Engineering, Yale University, New Haven, CT, 2Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, 3Surgery, Yale University, New Haven, CT, 4Immunobiology, Yale University, New Haven, CT

    *Purpose: Organ transplant is a highly successful therapy for patients facing end stage organ failure. However, there is a severe lack of transplantable organs which…
  • 2020 American Transplant Congress

    Early Impact of Interleukin-6 Blockade on the Distribution of Peripheral Blood Immune Cell Subpopulations – 3-Month Results of a Phase 2 Trial Evaluating Clazakizumab in Late Antibody-Mediated Rejection

    K. A. Doberer1, G. A. Boehmig1, M. Streitz2, S. Schlickeiser2, F. Bauernfeind1, A. Spittler3, B. Jilma4, F. Eskandary1, E. Chong5, S. Schranz4, K. Budde6, M. Dürr6

    1Department of Medicine III, Medical University of Vienna, Vienna, Austria, 2Charité Universitätsmedizin Berlin, Institute of Medical Immunology, Berlin, Germany, 3Center of Translational Research, Medical University of Vienna, Vienna, Austria, 4Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria, 5Vitaeris Inc., Vancouver, BC, Canada, 6Division of Nephrology and Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany

    *Purpose: Interleukin-6 (IL-6) is considered to play a critical role within the multifacted pathophysiological process of antibody-mediated rejection (ABMR), including modulation of regulatory T cells…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences